Search

University of Leeds

Kyverna Therapeutics and David Porter, Director, Cell Therapy and Transplant, University of Pennsylvania

Kissei Pharmaceutical Co., Ltd., International University of Health and Welfare, and Shunsuke Furuta, Associate Professor, Department of Allergy and Clinical Immunology

HERF, Head, Uveitis Services

Kyverna Therapeutics and David Simon, Principal Investigator, Head of the Clinical Trial Unit

Shanghai Changzheng Hospital

Children's Hospital of Chongqing Medical University and Mao Jianhua, professor

National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Office of Rare Diseases (ORD), National Center for Advancing Translational Sciences (NCATS), and Rare Diseases Clinical Research Network

The Cleveland Clinic, Bristol-Myers Squibb, University of Pennsylvania, National Institutes of Health (NIH), and National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Travere Therapeutics, Inc.

Lingyun Sun, Chief physician

Medical Research Council

Merck Sharp & Dohme LLC and Dimitrios Chanouzas, Consultant Nephrologist

Ministry of Health, France

Genentech, Inc. and Ulrich Specks, MD, Principal Investigator

Ministry of Health, France

Duke University and University of South Florida

Shanghai First Song Therapeutics Co., Ltd and Li Sun, Professor and Chief Physician, Head of the Department of Rheumatology and Immunology, The First Affiliated Hospital of Wenzhou Medical University

National Research Agency, France

GlaxoSmithKline

Xu huji, Professor and Chief Physician, Head of the Department of Rheumatology and Immunology, Shanghai Changzheng Hospital.

Paul Scherrer Institut, Center for Proton Therapy